# US 10,246,715 B1 · CpG-oligodeoxynucleotide, immunogenic composition including the same, and method of inducing immune response by the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,246,715 B1 - Document ID: US10246715B1 - Status: Granted - Kind: B1 - Application number: 15/722,949 - Filed: 2017-10-02 - Published: 2019-04-04 - Granted: 2019-04-02 - Earliest claimed: 2017-10-02 - Assignees: National Health Research Institutes - Applicants: National Health Research Institutes - Inventors: Tsung-Hsien Chuang; Da-Wei Yeh; Chao-Yang Lai; Yi-Ling Liu; Chih-Hao Lu - Web page: https://patentgrep.com/patent/US10246715B1 ## CPC - C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs - A61K 31/7088: Compounds having three or more nucleosides or nucleotides - A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links - A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants - A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants} - C12N 2310/17: Immunomodulatory nucleic acids - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract A CpG-oligodeoxynucleotide (CpG-ODN) for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof in a host is provided. The CpG-ODN includes one or more copies of the sequences of GTCGTT, one or more copies of the sequences of GTT and one or more copies of the sequences of TTTT, wherein at least one copy of the sequence of GTCGTT is encoded between the sequence of GTT and the sequence of TTTT. Further, an immunogenic composition including the CpG-ODN and a method of inducing immune response by the same are also provided. ## Claims ### Claim 1 A CpG-oligodeoxynucleotide (CpG-ODN) for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof in a host, comprising: one or more copies of the sequence of GTCGTT; one or more copies of the sequence of GTT; and one or more copies of the sequence of TTTT; wherein at least one copy of the sequence of GTCGTT is encoded between the sequence of GTT and the sequence of TTTT, and the CpG-ODN comprises the sequence of SEQ ID NO: 1. ### Claim 2 A CpG-oligodeoxynucleotide (CpG-ODN) for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof in a host, comprising: one or more copies of the sequence of GTCGTT; one or more copies of the sequence of GTT; and one or more copies of the sequence of TTTT; wherein at least one copy of the sequence of GTCGTT is encoded between the sequence of GTT and the sequence of TTTT, and the CpG-ODN has having a length of 19 nucleotides. ### Claim 3 A CpG-oligodeoxynucleotide (CpG-ODN) for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof in a host, comprising: one or more copies of the sequence of GTCGTT; one or more copies of the sequence of GTT; and one or more copies of the sequence of TTTT; wherein at least one copy of the sequence of GTCGTT is encoded between the sequence of GTT and the sequence of TTTT, and the CpG-ODN comprises the sequence of SEQ ID NO: 2 or SEQ ID NO: 3. ### Claim 4 (depends on 1) The CpG-ODN as in claim 1, wherein the host is selected from the group consisting of human, ayes, rodent and pisces. ### Claim 5 (depends on 1) An immunogenic composition for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof, comprising: the CpG-ODN as in claim 1; and a vehicle, an excipient or a combination thereof. ### Claim 6 (depends on 5) The immunogenic composition as in claim 5, further comprising an antigen selected from the group consisting of: virus, bacterium, protozoa, and tumor. ### Claim 7 (depends on 1) A method of inducing an immune response of a host for treating or preventing a disorder, comprising: preparing an immunogenic composition for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof, including an effective dose of a CpG-ODN, wherein the CpG-ODN is as in claim 1; and administrating the immunogenic composition to the host. ### Claim 8 (depends on 7) The method as in claim 7, wherein the host is selected from the group consisting of human, ayes, rodent and pisces. ### Claim 9 (depends on 7) The method as in claim 7, wherein the effective dose is 0.01 mg/kg body weight to 20 mg/kg body weight. ### Claim 10 (depends on 7) The method as in claim 7, wherein the disorder is selected from the group consisting of breast cancer, prostate cancer, melanoma, lymphoma, non-small-cell lung cancer, basal cell carcinoma, glioblastoma, ovarian cancer, and an infectious disease induced by hepatitis B virus, B. anthrax, malaria, S. pneumoniae, herpes simplex virus, influenza virus or a combination thereof. ### Claim 11 (depends on 7) The method as in claim 7, wherein the administrating comprises administrating orally or by means of injection. ### Claim 12 (depends on 2) An immunogenic composition for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof, comprising: the CpG-ODN as in claim 2; and a vehicle, an excipient or a combination thereof. ### Claim 13 (depends on 3) An immunogenic composition for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof, comprising: the CpG-ODN as in claim 3; and a vehicle, an excipient or a combination thereof. ### Claim 14 (depends on 2) A method of inducing an immune response of a host for treating or preventing a disorder, comprising: preparing an immunogenic composition for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof, including an effective dose of a CpG-ODN, wherein the CpG-ODN is as in claim 2; and administrating the immunogenic composition to the host. ### Claim 15 (depends on 3) A method of inducing an immune response of a host for treating or preventing a disorder, comprising: preparing an immunogenic composition for inducing a TLR9 activated immune response, a TLR21 activated immune response or a combination thereof, including an effective dose of a CpG-ODN, wherein the CpG-ODN is as in claim 3; and administrating the immunogenic composition to the host.